Industry News for MS
Find the latest news and headlines on new drug discoveries, healthcare research, and development.
Press Release: New 48-Week Frexalimab Phase 2 Data Support Potential For High Sustained Efficacy In Multiple Sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a [...]
The Siegel Rare Neuroimmune Association Marks 30 Years of Improving Quality of Life for People With Rare Neuroimmune Disorders
Not-for-profit celebrates past achievements and looks to the future POWELL, Ohio, February 29, 2024 (Newswire.com) - The Siegel Rare [...]
The Language of MS: How Much Does It Matter?
I got an email recently from someone well up the chain of command at a multiple sclerosis (MS) patient advocacy organization. The purpose [...]
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete [...]
Positive Phase III results for Genentech’s Ocrevus (ocrelizumab)
Phase III OCARINA II trial met primary and secondary endpoints Ocrevus 10-minute injection has the potential to further improve the [...]
Helius launches UpScript telehealth e-commerce site
PDF Version New Partnership with UpScript Provides Access to Care, Delivers PoNS Devices to Doorsteps NEWTOWN, Pa., Jan. 03, 2023 [...]
Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023
Eligible patients will receive full MS patient support program through Cycle Vita™ Boston, Massachusetts and San Jose, California – [...]
Genentech to present new Ocrevus (ocrelizumab) data in multiple sclerosis & NMOSD research at ECTRIMS
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® (ocrelizumab) data and continued [...]
US FDA – Ocrevus prescribing information to include warnings for Colitis and PML
Labeling updates to Ocrevus (ocrelizumab) injection, for intravenous use for the treatment of multiple sclerosis (MS) will be [...]
Janssen Pharmaceuticals U.S. transparency report
Janssen Pharmaceuticals recently published their sixth annual Janssen U.S. Transparency Report. The Report explains Janssen’s sustained [...]
Genentech premiers #MSVisibility 2022
Genentech is very excited to kick off #MSVisibility 2022 this coming Monday, March 28th with the launch of a new, bilingual video, focusing [...]
Sanofi’s 2022 annual pricing principles report
I’m pleased to share with you Sanofi’s 2022 Annual Pricing Principles report. This is the sixth consecutive edition of this [...]
New preclinical tolebrutinib data demonstrated superior brain penetration and potency
Preclinical findings showed that tolebrutinib, among the investigational BTK inhibitors tested, had the best combination of brain [...]
Study: Epstein-Barr virus can cause multiple sclerosis
Researchers from Harvard University recently found that the Epstein-Barr virus (EBV), which is most known for leading to mononucleosis, is [...]
Ublituximab, potential relapsing multiple sclerosis therapy, up for FDA approval
TG Therapeutics has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational [...]
Introducing Atara Biotherapeutics: the role of EBV in multiple sclerosis and the Phase II EMBOLD study
Consortium of Multiple Sclerosis Centers (CMSC) and Atara Biotherapeutics on Thursday - June 10, 2021 at 7:00 PM - 8:00 PM ET on an [...]
Study on cognitive processing speed changes in RMS subjects treated with Ozanimod
Bristol Myers Squibb is conducting a Phase 3b Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing [...]
#MSVisibility virtual concert: recording now available
#MSVisibility Virtual Concert Thank you for your interest in the first-ever #MSVisibility Virtual Concert, a free event to celebrate and [...]
Phase 1/2 study to evaluate the safety and efficacy of ATA188 in progressive multiple sclerosis
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the [...]
New data for Ocrevus disease progression (ocrelizumab) reinforce significant slowing
– 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity [...]
New Genentech data at 2021 AAN highlight impact & breadth of neuroscience portfolio
Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy [...]
Janssen announces U.S. FDA approval of PONVORY™ (ponesimod)
Head-to-head pivotal clinical trial results showed PONVORY™ treatment led to nearly a third fewer annual relapses than [...]
FDA approval of intramuscular Plegridy (Peginterferon beta-1a)
Please be advised of the recent approval by the FDA for intramuscular Plegridy (Peginterferon beta-1a) and an update to other sections [...]
Dr. Thrower discusses management, different types of multiple sclerosis fatigue
https://youtu.be/vtwauNrp8Jo Ben Thrower, MD, Medical Director, Andrew C. Carlos Multiple Sclerosis Institute, talks about different [...]
New data further reinforce Genentech’s Ocrevus (ocrelizumab) as effective treatment
7 5% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease [...]
Genentech’s enspryng for Neuromyelitis Optica Spectrum Disorder
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a [...]
Mylan brings critical access to the multiple sclerosis community
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]
A letter from Lemtrada regarding its home phlebotomy partner, EMSI
Good Day Lemtrada Patient – On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination [...]
Inebilizumab approved for treatment of Neuromyelitis Optica Spectrum Disorder
The US FDA has approved inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 [...]
Rebif® U.S. label includes pregnancy outcomes & lactation information
- Label update is based on data from a large register-based study, as well as other published studies over several decades - Multiple [...]
Avonex and Plegridy label updates
The Plegridy (peginterferon beta-1a) Prescribing Information and the Avonex (interferon beta-1a) Prescribing Information was updated in the [...]
FDA approves Zeposia (Ozanimod), oral therapy for all with relapsing multiple sclerosis
The U.S. Food and Drug Administration (FDA) has approved Zeposia (ozanimod) oral capsules to treat adults with relapsing forms [...]
MedDay report top-line data from trial “SPI2” for treatment of progressive forms of multiple sclerosis
Paris, France, March 10, 2020 – MedDay Pharmaceuticals announced today that the second pivotal Phase III trial (SPI2) of its [...]
U.S. health officials urge Americans to prepare for spread of Coronavirus
CHICAGO/WASHINGTON (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday alerted Americans to begin preparing [...]
Participate in a study evaluating a potential treatment options for RRMS relapses
The OPTIONS Study is looking at how well a study drug works for adults with relapsing-remitting multiple sclerosis (RRMS) who are currently [...]
Brain activity patterns linked with improved learning and memory in multiple sclerosis
A recent article by Kessler Foundation researchers demonstrated g people with multiple sclerosis (MS). The article, "Brain activation [...]
Robotic ‘trousers’ could help thousands of multiple sclerosis sufferers stand and walk again
Robotic ‘trousers’ could help thousands of people left unable to stand or walk due to multiple sclerosis find their feet again. The [...]
Use of DMTs changing ‘natural history’ of relapsing multiple sclerosis, study says
People with relapsing multiple sclerosis (MS) have a better prognosis and a slower progression to disability since the introduction of [...]
FDA approves first generics for common multiple sclerosis drug
The FDA has approved 3 applications for generics of fingolimod (Gilenya, Novartis). These are the first generics of the drug, which treats [...]
Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with [...]
NeurologyLive™ adds CMSC to its Strategic Alliance Partnership program
CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLive™, a multimedia platform dedicated to providing health care professionals treating [...]
Kessler scientists receive grant to study exercise benefits in multiple sclerosis
East Hanover, NJ. October 7, 2019. With a grant from the Consortium of Multiple Sclerosis Centers, John DeLuca, PhD, Helen Genova, PhD, of [...]
EMD Serono initiates pivotal Phase III program for investigational Evobrutinib in RMS
ROCKLAND, Mass., Sept. 10, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. [...]
Genentech presents new six-year Ocrevus (Ocrelizumab) data
Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair [...]
Genentech’s Satralizumab significantly reduced relapse risk
Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at [...]
Genentech presents new Ocrevus (Ocrelizumab) biomarker data
Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in RMS [...]
Dr. Daniel Kantor highlights multiple sclerosis treatments and what is in the pipeline
The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the next new class of therapies probably [...]
Multiple sclerosis relationships improved by togetherness and communication, study suggests
Relationships between multiple sclerosis patients and their intimate partners were enhanced when the couple worked together to make [...]
Press release – Genentech to present piviotal data at ECTRIMS
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis [...]
Social cognition, mood and fatigue in multiple sclerosis
Study by MS research team links deficits in social cognition with fatigue, depressive symptomatology, and anxiety Date: August 29, [...]
The genetic and environmental factors that can cause multiple sclerosis
Researchers say genetic makeup is a factor, but so are smoking, obesity, vitamin D, and viral infections. A combination of genetic and [...]
Rutgers Health leading program to support multiple sclerosis children
Rutgers Health is leading the Pediatric Multiple Sclerosis and Demyelinating Diseases Program, the only program in the state of New [...]
Dr. Anne Cross discusses strides In multiple sclerosis research, recent award
Years ago, when many multiple sclerosis researchers believed that a type of immune cell known as a T-cell was the cause of the disease, Dr. [...]
EMD Serono’s embracing carers launches ‘Time Counts’ to raise 1M minutes of support
Rockland, MA – EMD Serono, the biopharmaceutical company of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that [...]
Alexion’s Soliris gets new, and lucrative, rare disease indication
June 28, 2019 (This news originally appeared in PharmaPhorum Website [...]
Kessler researchers explore social cognitive deficits in progressive multiple sclerosis
East Hanover, NJ. June 25, 2019. A recent study by Kessler Foundation researchers provided new findings about the nature of social [...]
Billings Clinic hosts its first multiple sclerosis health and well-being symposium
The Billings Clinic hosted its first Multiple Sclerosis Health and Well-Being Symposium. It was a day-long educational seminar for people [...]
Study moves closer to identifying cause of multiple sclerosis
A study by the University of British Columbia made a scientific advance that researchers hope will lead to the development of preventative [...]
UCLA researchers work to advance treatment targeting source of multiple sclerosis
UCLA researchers are developing the first multiple sclerosis treatment that could target the cause of the disease, instead of simply [...]
Genentech presenting new Ocrevus (Ocrelizumab) data at AAN Meeting
Genentech to Present New OCREVUS (ocrelizumab) Data Analyses Showing Significant Reduction of Disability Progression in Relapsing and [...]
MSAA recognizes ten years of artwork from individuals with multiple sclerosis
CHERRY HILL, N.J., May 2, 2019 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to recognize ten years of [...]
FDA approves MAVENCLAD® (Cladribine) tablets
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's [...]
OHSU doctors part of ‘breakthrough’ research on treating multiple sclerosis
PORTLAND, Ore. (KATU) – They're calling it a potential game-changer. Doctors at Oregon Health and Science University are part of a new [...]
Anne Cross, neurologist with pioneering work into B-cells/multiple sclerosis, awarded John Dystel Prize
This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS chair in the [...]
Novartis gets FDA approval for Mayzent (Siponimod), the first oral drug to treat SPMS
EAST HANOVER, N.J., March 27, 2019 /PRNewswire/ --Novartis today announced that the US Food and Drug Administration (FDA) has approved [...]
Novartis receives FDA approval for MAYZENT (Siponimod)
- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis [...]
Dose-finding study for SAR442168 in relapsing multiple sclerosis
Brief Summary: Primary Objective: To determine the efficacy of SAR442168 in reducing the number of new brain lesions reported in [...]
BrainStorm announces first patient in phase 2 clinical trial progressive multiple sclerosis
NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE)—BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing [...]
Depression, psychological distress symptoms affect multiple sclerosis patients’ quality of life
Depression and psychological distress symptoms can have a huge effect on the way multiple sclerosis (MS) patients view their well-being, [...]
FDA accepts BrainStorm’s NurOwn® IND application for progressive multiple sclerosis
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative [...]
Positive late-breaking phase II data evaluating investigational oral therapy
First Bruton’s Tyrosine Kinase inhibitor (BTKi) demonstrating clinical proof-of-concept in relapsing multiple sclerosis (RMS) [...]
TG Therapeutics, Inc. announces final phase 2 multiple sclerosis data presentation at ECTRIMS
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial ECTRIMS data review conference call to be held [...]
Novartis announces FDA filing acceptance of Siponimod (BAF312)
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating [...]
New efficacy and safety data on multiple sclerosis portfolio to be presented
Late-breaking Phase II primary endpoint data for investigational therapy evobrutinib, the first oral BTK inhibitor to show [...]
Press release – Ocrevus data show early initiation reduces progression
Dear Advocates, OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in [...]
Novartis announces PARADIGMS study demonstrating benefit of Gilenya®
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents [...]
Researchers identify new subtype of multiple sclerosis
Researchers have discovered a new subtype of multiple sclerosis (MS), providing a better understanding of the disease and potentially [...]
MRI tests may help doctors predict multiple sclerosis progression in patients
Researchers have apparently found a way to help predict multiple sclerosis disease progression one year after an initial [...]
Researchers have a new theory about what may cause multiple sclerosis
When the following headline in the Australian newspaper the Herald Sun caught my eye recently, I was cautiously intrigued: “Doctors [...]
FDA accepts file for Cladribine tablets as potential treatment for relapsing forms of multiple sclerosis
PDF ROCKLAND, Mass., July 30, 2018 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and [...]
Temperament can play a big role in quality of life with multiple sclerosis
Researchers say if a person with multiple sclerosis is irritable or anxious, it can make overcoming the obstacles of their disease much [...]
Genentech announces new Ocrevus (Ocrelizumab) data for PPMS
Dear Advocates, We are pleased to announce that new OCREVUS® (ocrelizumab) data will be presented at the 4th Congress of the European [...]
AAN publishes guideline on disease-modifying therapies for multiple sclerosis
The AAN published a new guideline, Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis, in Neurology® [...]
New Ocrevus (Ocrelizumab) data demonstrate reductions In activity & progression In RMS
We are pleased to announce that new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual [...]
Phase III data in the lancet show Novartis outcomes in secondary progressive multiple sclerosis
EAST HANOVER, N.J., March 22, 2018 – Novartis today announced that the full results from the Phase III EXPAND study of oral, [...]
Abbvie and Biogen pull multiple sclerosis drug Zinbryta following urgent EMA safety review
Seven of the cases were identified in Germany and one in Spain, and included encephalitis and meningoencephalitis. The pharma pair said in [...]
CVS/Aetna combo a formidable pharma rival when it comes to access
Last month's unusual consolidation of healthcare provider CVS Health with insurance company Aetna spawned a new behemoth that could pose a [...]
Fruits and vegetables may help reduce symptoms of multiple sclerosis: study
Eating a healthy diet containing loads of fruits and vegetables along with whole grains may lower disability and reduce symptoms of [...]
Increased epilepsy risk identified in multiple sclerosis
A direct correlation exists between the presence and severity of multiple sclerosis (MS) and the risk for epilepsy, according to study [...]
National Multiple Sclerosis Society endorses multiple sclerosis “NARCRMS” data registry
NEW YORK, Dec. 4, 2017 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society is proud to announce its endorsement of [...]
Mayo Clinic develops test to distinguish other demyelinating diseases from multiple sclerosis
The Mayo Clinic has developed a test that allows doctors to distinguish other inflammatory demyelinating diseases from multiple sclerosis [...]
Cognitive impairment worse among PPMS than RMS patients, German study fnds
Patients with primary progressive multiple sclerosis (PPMS) have more severe cognitive impairment than those with relapsing-remitting [...]
5 areas of research that could change the future of multiple sclerosis treatment
Multiple sclerosis is a disease that affects the nervous system, disrupting messages between the brain and the rest of the body resulting [...]
Breastfeeding linked to reduced risk of multiple sclerosis – study
New York: Mothers who breastfeed for at least 15 months over one or more pregnancies may be 53 per cent less likely to develop multiple [...]
12 ways amazon’s alexa can help people with multiple sclerosis
“Alexa” is Amazon’s talking service that acts as a virtual personal assistant. According to tomsguide.com, as part of the company’s [...]
OMRF multiple sclerosis center wins top multiple sclerosis research award
OKLAHOMA CITY — The Oklahoma Medical Research Foundation's Multiple Sclerosis Center of Excellence won the Labe Scheinberg Award at the [...]
Minocycline may slow progression from Clinically Isolated Syndrome to multiple sclerosis
Minocycline, a broad-spectrum tetracycline antibiotic, reduces risk of conversion from clinically isolated syndrome (CIS) to multiple [...]
Multiple aclerosis – antioxidant may slow disease progression
In a pilot study, researchers found that taking a high dose of lipoic acid every day for 2 years reduced whole brain atrophy among patients [...]
Research sheds light on who’s multiple sclerosis could worsen
A preliminary study by senior author Bianca Weinstock-Guttman, MD, has heightened researchers’ understanding about which adults with [...]
Sodium intake and its association with multiple sclerosis progression
HealthDay News — There is no association between average 24-hour urine sodium levels and conversion from clinically isolated syndrome [...]
New multiple sclerosis drug, backed by 40 years of research, could halt disease
A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis (MS) is holding new hope for [...]
‘MS From the Inside Out’ uses virtual reality to share what life for patients is like
Virtual reality (VR) technology is most commonly associated with gaming and entertainment, but it’s expanding into a variety of clinical [...]
Multiple sclerosis study in cancer breakthrough
A DRUG that helps the immune system destroy cancer has been developed by US scientists. It dramatically shrank deadly skin, brain and [...]
Multiple sclerosis is more complex than once thought: study
Having a disabling disease can making living very difficult, especially when the source of the disability is not well understood. Some [...]
Multiple sclerosis starts five years before onset of disease, study suggests
Symptoms of multiple sclerosis (MS) can appear 5 years before onset of the disease, according to a new study published in Lancet [...]
The hidden costs of multiple sclerosis
MS is sneaky. It is expert at evading detection and diagnosis, and often brings a host of invisible symptoms that may come and go at [...]
What triggers multiple sclerosis? scientists may have identified the culprit
Scientists have identified a cellular mechanism that may be responsible for the development of multiple sclerosis (MS), and could serve as [...]
Vitamin D deficiency affects cognition in multiple sclerosis
Results of a study published in a recent issue of Scientific Reports1 showed significant improvements in cognitive performance among [...]
Nose2brain – project to improve multiple sclerosis therapy
Medically active substances are usually distributed via the blood – either directly or indirectly. In many diseases, however, it is vital [...]
Biogen Idec to present new two-year data from the PLEGRIDY phase 3 advance study
Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 Advance Study at AAN Annual [...]
New survey finds multiple sclerosis patients struggle with misdiagnosis and invisible symptoms
PHILADELPHIA, PA --(Marketwired - April 27, 2017) - MS in America 2017, a national survey of more than 5,300 individuals diagnosed with [...]
Why the future of science is crucial to the multiple sclerosis community
Everything around us, and within us, begins with science. Science is important to the future of humanity’s well-being. Science is what [...]
Is ‘no evidence of disease activity’ a misnomer in multiple sclerosis?
BOSTON -- Multiple sclerosis patients who are not having relapses, not becoming more disabled according to a standard measure, and with MRI [...]
How biotech is mastering multiple sclerosis: a review
Multiple sclerosis (MS) is an autoimmune disease that affects the nervous system, and around 2 million people around the world live with [...]
Health reform: how is pharma affected?
Reforming the health care industry is an increasingly complex challenge due to multiple layers of legislation already in place and the [...]
Brain protein may unlock key to multiple sclerosis treatment – study
Scientists have made significant progress in finding the cause of multiple sclerosis (MS), discovering the presence of a protein in brain [...]
Research moves closer to unraveling mystery cause of multiple sclerosis
A new study has made a major new discovery towards finding the cause of multiple sclerosis (MS), potentially paving the way for research to [...]
Glove with sensors measures spasticity more accurately than physicians
A multidisciplinary team at the University of California at San Diego has come up with a computerized glove used as a sensor to measure [...]
Symptoms of multiple sclerosis start to show five years before its onset
People with multiple sclerosis start showing its symptoms five years before the onset of the disease, claim Canadian [...]
Researchers analyze multiple sclerosis life expectancy, survival and mortality in 60-year study
A 60-year longitudinal multiple sclerosis (MS) study in a Norwegian cohort analyzing life expectancy, survival and mortality concluded that [...]
Alexa, tell me about multiple sclerosis
Alexa, Amazon’s little voice-activated information box, has just received a multiple sclerosis infusion. As part of MS Awareness [...]
Pilot study may lead to telemedicine benefiting people with multiple sclerosis
Telemedicine, which allows healthcare professionals to evaluate, diagnose and treat patients at a distance with telecommunications [...]
Researchers make major brain repair fiscovery in fight against multiple sclerosis
The research study, led by Dr Yvonne Dombrowski and Dr Denise Fitzgerald at the Wellcome-Wolfson Institute for Experimental Medicine at [...]
5 benefits of having a pet when you have multiple sclerosis
As part of MS Awareness Month, we’re looking at different aspects of living with multiple sclerosis and some of the things patients [...]
Here’s How You Can Prevent, Manage Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic disease that affects around 2.3 million people worldwide and can cause blurred vision, slurred speech, [...]
How Stress Affects Multiple Sclerosis Symptoms
As part of MS Awareness Month, we want to talk about the role stress plays in multiple sclerosis. Having any chronic illness is likely to [...]
Horseback Riding Helps People with Movement Disabilities, Review of 16 Studies Concludes
Riding and other activities with horses can help adults and children with the balance, gait, and psychomotor disorders that are hallmarks [...]
People with MS are Three-six Times More Prone to Seizures than Others, Study Reports
People with multiple sclerosis (MS) are three to six times more likely to develop epilepsy than the general population, a study [...]
Multiple Sclerosis – New Technology Improves Cognition
Multiple sclerosis (MS) is an often disabling neurological disease that affects one's muscles, vision, mood, and concentration. MS is [...]
11 Subtle Early Signs of Multiple Sclerosis – The Sooner You Catch it the Better
Multiple sclerosis is one of those scary health concerns that rarely comes up in conversation. And yet, learning about and recognizing the [...]
HackensackUMC Opens Multiple Sclerosis Center
Hackensack University Medical Center has opened a new multiple sclerosis center. “We are very excited to offer a comprehensive center [...]
First Blood Biomarker for Multiple Sclerosis Discovered
Although there is no known cure for multiple sclerosis (MS), there are treatments that can help prevent new attacks and improve function [...]
MS – New Blood Test Can Identify Types of MS and if Treatments are Working
At the moment, patients have to have an array of expensive tests to determine what kind of MS they have. The study, published in Nature [...]
Generic Form of Copaxone, GTR, Safe and Effective, Study Confirms
An extension trial assessing generic glatiramer acetate (GTR) treatment in multiple sclerosis (MS) patients found that the formulation is [...]
Researchers fFnd Clues to Multiple Sclerosis in Blood
In a new study led by Indian-American researchers at Brigham and Women’s Hospital, Harvard Medical School, suggests that microRNAs in the [...]
Sense of Smell is Impaired in Half of Multiple Sclerosis Patients in Study
Many multiple sclerosis (MS) patients have a reduced sense of smell, and the more relapses they have, the worse the problem, according to a [...]
Epileptic Seizures in Multiple Sclerosis May Suggest Shared Pathology
Patients with multiple sclerosis (MS) who experience seizures are more likely to be younger at the age of MS onset than patients with MS [...]
Grief, Self-Preservation and Multiple Sclerosis
Grief can weaken our immune system, elevate our blood pressure, and affect our overall health. During a loss, especially one of the [...]
Template Improves Quality of Report on MRI for Multiple Sclerosis
Use of a standardized template for reporting of brain magnetic resonance images (MRIs) in patients with multiple sclerosis (MS) improves [...]